Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

被引：0
|
作者：
Charles E. Frost
Van Ly
Samira M. Garonzik
机构：
[1] Bristol Myers Squibb,Research and Development
来源：
Drugs in R&D | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：375 / 384
页数：9
相关论文
共 50 条
  • [1] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [2] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [3] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [4] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [5] Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat
    Khosravan, R
    Grabowski, B
    Mayer, M
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
  • [6] Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment
    Zimmerman, JJ
    Lasseter, KC
    Lim, HK
    Harper, D
    Dilzer, SC
    Parker, V
    Matschke, K
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12): : 1368 - 1372
  • [7] Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
    Desai, Amit
    Schmitt-Hoffmann, Anne-Hortense
    Mujais, Salim
    Townsend, Robert
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3025 - 3031
  • [8] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
  • [9] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 998 - 1010
  • [10] Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
    S. G. Simonson
    P. D. Martin
    P. Mitchell
    D. W. Schneck
    K. C. Lasseter
    M. J. Warwick
    [J]. European Journal of Clinical Pharmacology, 2003, 58 : 669 - 675
12345